Skip to main content
Article thumbnail
Location of Repository

R&D Portfolios and Pharmaceutical Licensing

By Junichi Nishimura and Yosuke Okada

Abstract

We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competitors in R&D and product markets. The data collected comprises 329 license-outs and 434 license-ins closed by 54 Japanese pharmaceutical companies between 1997 and 2007. We pay special attention to stage-specific licensing by dividing the innovation process into an early stage and a late stage. Estimates from the fixed-effect GMM model reveal that drug pipelines significantly affect stage-specific licensing. Particularly, the state of drug pipelines is leveled off by license-outs at the early stage and license-ins at the late stage. Theoretical implications are also discussed.R&D portfolios, licensing, pharmaceutical industry, drug pipelines

OAI identifier:

Suggested articles

Citations

  1. (2009). A Capability-Based Framework for Open Innovation: Complementing Absorptive Capacity,
  2. (1994). A microeconometric analysis of technology transfer: The case of licensing agreements of Japanese firms,
  3. (2009). Absorptive capacity, environmental turbulence, and the complementarity of organizational learning processes,
  4. (1990). Absorptive capacity: A new perspective on learning and innovation,
  5. (2006). Attitude to externally organizing knowledge management tasks: A review, reconsideration and extension of the NIH syndrome,
  6. (1990). Choosing the competition and patent licensing,
  7. (2010). Determinants of proactive and reactive technology licensing: A contingency perspective,
  8. (1984). Deterrence through market sharing: A strategic incentive for licensing,
  9. (2006). Generalized reduced rank tests using the singular value decomposition,
  10. (2010). Ideas for rent: An overview of markets for technology,
  11. (1989). Innovation and learning: The two faces of R&D,
  12. (2007). International comparison of biotech firms between Japan and the United States,
  13. (2010). Inventions under siege? The impact of technology competition on licensing,
  14. (2004). Licensing as a commercialization strategy for new technology-based firms,
  15. (2008). Licensing or not licensing? An empirical analysis of the strategic use of patents by Japanese firms,
  16. (2003). Licensing the market for technology,
  17. (2004). Market structure and technology licensing: Evidence from US manufacturing,
  18. (2001). Markets for technology and their implications for corporate strategy,
  19. (2001). Markets for technology: The economics of innovation and corporate strategy,
  20. (2007). Mergers and acquisitions in the pharmaceutical and biotech industries,
  21. (2003). Open innovation: The new imperative for creating and profiting from technology,
  22. (2006). Patent protection, complementary assets, and firm’s incentives for technology licensing,
  23. (1995). Patents and productivity growth at the industry level:
  24. (1986). Profiting from technological innovation,
  25. (2009). Public-Private linkage in biomedical research in Japan: Lessons of the 1990s,
  26. (2005). R&D boundaries of the firm: An estimation of the double-hurdle model on commissioned
  27. (2001). Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research,
  28. (1996). Scale, scope, and spillovers: The determinants of research productivity in drug discovery,
  29. (2007). Strategic management of R&D pipelines with cospecialized investments and technology markets,
  30. (2006). Technology licensing partners,
  31. (2001). Technology regimes and new firms formation,
  32. (2005). The determinants of contractual formation in licensing: Firm size and patent thicket,
  33. (1996). The economics of science,
  34. (2008). The impact of uncertain intellectual property rights on the market for ideas: Evidence from patent grant delays,
  35. (2006). The incidence of cross-licensing: A theory and new evidence on the firm and contract level determinants,
  36. (1997). The increasing linkage between U.S. technology and public science,
  37. (2006). The licensing dilemma: Understanding the determinants of the rate of technology licensing,
  38. (2007). The market for patents in Europe,
  39. (2006). The outsourcing of R&D through acquisitions in the pharmaceutical industry,
  40. (1999). The pharmaceutical industry and the revolution in molecular biology: Interactions among scientific, institutional, and organizational change,
  41. (2003). The price of innovation: New estimates of drug development costs,
  42. (2010). Timing of licensing: Theory and empirics,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.